Krill Oil Impresses in Pharma Study
CaPre krill oil lowered triglycerides more than 20% in eight weeks.
A pharma-grade krill oil called CaPre has impressed in a clinical trial on subjects with high triglycerides.
More than 200 subjects participated in the eight-week, Phase II clinical trial in which subjects consumed 4 g or 2 g of the purified krill oil daily. At eight weeks, triglycerides dropped by more than 20% with each dosage. The higher dosage improved HDL, LDL, and non-HDL cholesterol too. It also lowered triglycerides 15.5% in as little as four weeks.
Researchers reported no serious adverse events from consuming the krill drug, which bodes well for future therapy using krill alone or in combination with statins.
CaPre krill oil is produced by Acasti Pharma, a subsidiary of the krill oil supplier Neptune Technologies & Bioressources (Laval, QC, Canada). Neptune’s krill oils are also available for use in dietary supplements, animal feed, and nursing feed.
